Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Alcobra Ltd.
  • Athersys Inc.
  • BioCryst Pharmaceuticals Inc.
  • Celldex Therapeutics Inc.
  • Cempra Inc.
  • Chimerix Inc.
  • Five Prime Therapeutics
  • Incyte Corp.
  • Isis Pharmaceuticals Inc.
  • Navidea Biopharmaceuticals Inc.
  • NeoStem Inc.
  • Novavax Inc.
  • Omeros Corp.
  • Sarepta Therapeutics Inc.
  • Tekmira Pharmaceuticals Inc.
  • Tetraphase Pharmaceuticals Inc.

Steve Brozak

WBB Securities

Image: Steve Brozak

Steve Brozak is the managing partner and president of WBB Securities, an investment bank and financial analytical firm engaged in the biotechnology, pharmaceutical and medical device sectors. Before cofounding WBB Securities, he worked for several Wall Street firms, including Salomon Brothers, Dean Witter, Cowen & Company, and Alex. Brown & Sons. As WBB Security's Senior Equity Analyst, Brozak has been acknowledged for his investment acumen and equity research performance by the major analyst ranking systems. In 2013, he was selected as the #2 ranked analyst in the pharmaceuticals sector by the StarMine/Financial Times Industry Analyst Awards system. The Wall Street Journal distinguished Brozak as its Best on the Street Medical Equipment and Supplies financial analyst in its 19th Annual Best on the Street Survey in 2011. In 2010, Brozak received StarMine Thompson Reuters/Financial Times Best Brokerage Analyst award for his selection of top-performing companies in the biotechnology space. With a 25-year track record in banking and analysis in the life sciences space, Brozak also works as media commentator on the life sciences sector on the web, on television, and in print media. Brozak served in the United States Marine Corps and now serves on the Secretary of the Navy's Navy and Marine Corps Retiree Council, where he focuses on healthcare, benefits and other veteran issues. He received a bachelor's degree and a master's degree in business administration from Columbia University, and also holds FINRA licenses 3, 7, 8, 24, 63, 65, 79, 86, 87 and 99.




Recent Interviews

Will Biotech Fire on All Cylinders in 2015? (12/30/14) Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early 2014 before rebounding, essentially following the upward trend that most experts forecast. What is in store for 2015? The Life Sciences Report turned to newsletter writer John McCamant and WBB Securities' Steve Brozak for insight.

Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak (11/13/14) What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corp.? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview with The Life Sciences Report. His military background, combined with 20 years as a biotech and medtech analyst, has allowed the WBB Securities cofounder to develop a reasoned perspective on how West Africa's Ebola epidemic might be humanely halted. Brozak also mentions small-cap names that could considerably enhance investors' portfolios.

Steve Brozak: Big-Picture Biotech Stocks Rule the Future (9/4/14) When Steve Brozak performs diligence on biotech stocks, he's always looking for an angle. Brozak, president and managing director at WBB Securities, wants to see how new technology platforms and novel ideas fit into tomorrow's healthcare system, which he believes will be unsustainable without therapies that work more efficiently and hold promise as true disease-modifying agents. In this interview with The Life Sciences Report, Brozak brings eight names to investors' attention. Given time, each holds the potential to be a huge gainer.

Recent Quotes

"With OMER's product, surgeons will receive a better product from a single-source, FDA-regulated company." (12/30/14) Omeros Corp. - The Life Sciences Report Interview with Steve Brozak More >

"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront." (12/30/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >

"OMER's Omidria is FDA-approved, proven sterile and safe, and reimbursable by payers." (11/13/14) Omeros Corp. - The Life Sciences Report Interview with Steve Brozak More >

"NBS will announce results from its Phase 2b PreSERVE-AMI trial on Nov. 17." (11/13/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >

"I think it would be easy for OMER to single-handedly take the market." (2/6/14) Omeros Corp. - The Life Sciences Report Interview with Steve Brozak More >

"NBS' initial trial data has been positive beyond expectations." (2/6/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >

"We believe ATHX is still undervalued." (2/6/14) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >

"There is exciting potential for CYTX's therapy." (2/6/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Steve Brozak More >

more comments

"We rate ATHX a Strong Buy for its fantastic progress in Japan and its continued positive work in the U.S." (1/9/14) Athersys Inc. - Steve Brozak, WBB Securities More >

fewer comments


Due to permission requirements, not all quotes are shown.